Pawel Olszowy writes about pharmaceutical manufacturing, with a focus on analytical development, process understanding, and planning regulatory changes across a product’s lifecycle. The posts discuss work at Polpharma API, including process analytical technology, impurity control, and GMP scale-up for complex drug components.
They are useful for explaining complex pharmaceutical manufacturing processes and regulatory planning to a specialist audience.
Best for
Brands focused on pharmaceutical manufacturing, CMC, or regulatory services seeking technical credibility.
Not for
Consumer health brands or software vendors seeking broad reach or simple product endorsements.
Key takeaways
A passing release test does not prove the process is under control.
Process analytical technology requires validated models and system integration.
Regulatory flexibility should be planned during the development stage.
Check first: Confirm audience role, engagement data, and specific results for technical topics.
Main ideas
Plan for post-approval change during development · A passing release test does not prove the process is under control · Treat process analytical technology as a multiyear operating change, not a tool purchase
Pawel Olszowy writes about pharmaceutical manufacturing, linking analytical development and process understanding to decisions about product quality, scale-up, and future changes.
Their posts explain why a passing batch test is not enough to understand impurity risk, what implementing Process Analytical Technology (PAT) takes, and why regulatory flexibility should be planned before approval.
They also describe Polpharma API’s collaboration with Celon Pharma on GMP scale-up and manufacturing for an antibody–drug conjugate program.
Their work offers clear, practical explanations of how pharmaceutical processes can become more understandable and adaptable.
Olszowy connects technical methods to manufacturing decisions.
In their post on impurity control, they distinguish passing release tests from understanding where impurities form, how they are purged, and whether the process will behave consistently.
Their PAT post shows that real-time monitoring depends on validated models, system integration, and cross-functional ownership—not simply installing analytical tools.
In their explanation of ICH Q12, they present regulatory flexibility as a development-stage choice that can prepare a product for later site, supplier, or capacity changes.
These examples show how analytical and regulatory planning can support reliable manufacturing and change across a product’s lifecycle.
Pawel Olszowy writes short, argument-led LinkedIn posts about pharmaceutical manufacturing.
Read more
Across all four posts, the priority is consistent: decisions that determine quality and supply resilience are made during development, not at release testing or after approval.
The posts typically open with a misconception or quoted question, explain the technical principle, and translate it into operating choices—established conditions and change protocols, impurity purge studies, or validated models and cross-functional PAT ownership.
They write from a Polpharma API vantage point, describing lifecycle management as part of development and PAT as part of a broader API manufacturing transformation.
Ask for publication dates to assess the order and recency of these themes.
Plan for post-approval change during development
Pawel Olszowy argues that waiting until after approval to consider post-approval changes is too late.
Read more
They see ICH Q12’s main advantage in designing flexibility into a product before the first commercial batch is released—not in speeding up variations.
Three tools underpin the argument: Established Conditions identify which dossier elements are critical to product quality and which can be managed through the Pharmaceutical Quality System; Post-Approval Change Management Protocols let a company agree with regulators in advance on the data, studies, and acceptance criteria for future manufacturing changes; and a Product Lifecycle Management document turns those commitments into a living commercial lifecycle roadmap.
Site transfers, supplier qualifications, capacity increases, process optimization, and supply-chain resilience all come after approval, so companies are better placed to manage them if they plan early.
At Polpharma, they say, lifecycle management is part of development.
A second manufacturing site or new supplier can trigger a lengthy CMC exercise unless established conditions and a change protocol are agreed while the product is still in development.
A passing release test does not prove the process is under control
Pawel Olszowy calls the belief that a passing release test proves a well-controlled process the most dangerous illusion in pharmaceutical manufacturing.
Read more
End-product testing confirms batch quality, but does not explain where an impurity formed, why it formed, whether the process stayed in control throughout manufacturing, or whether the next batch will behave the same way.
They advocate tracing impurities’ origin, fate, and purge across the process, then defining critical process parameters around impurity formation, designing meaningful in-process controls, demonstrating impurity purge scientifically, and treating end-product testing as confirmation rather than the primary safeguard.
Digital twins and model-based process development, they say, can help teams test process choices before locking in a process.
Simulate how mixing, temperature, reaction time, solvent selection, and crystallization conditions affect impurity formation and purge. This helps place in-process controls and analytical technology where they can have the greatest impact.
Treat process analytical technology as a multiyear operating change, not a tool purchase
Pawel Olszowy presents PAT as more than a set of instruments: it signals a shift in small-molecule manufacturing from retrospective quality control to real-time insight.
Read more
In-line and at-line tools monitor critical quality attributes during synthesis, granulation, and tableting.
But effective implementation, they argue, depends on validated analytical models, robust integration with platforms such as LIMS and MES, and cross-functional ownership across R&D, manufacturing, and QA.
They say implementation often takes years, not months.
The benefits they cite include faster, more confident batch-release decisions; earlier detection of process deviations; less rework and material loss; and more consistent technology transfer between sites.
At Polpharma API, they describe PAT as part of a broader transformation that increasingly embeds process data, automation, and advanced monitoring in development and production.
The gap between pilot analytical tools and dependable real-time control often comes down to validated models, integration with LIMS and MES, and shared ownership across R&D, manufacturing, and QA.
Analytical development underpins complex manufacturing programs
In a collaboration announcement, Pawel Olszowy says Polpharma API will support GMP scale-up and manufacturing of an MMAE-based payload–linker for an ADC program with Celon Pharma S.A.
Read more
They use the project to argue that analytical development gives process development and manufacturing teams the understanding to make informed decisions.
For complex payloads, linkers, and payload–linkers, that means profiling impurities, developing robust analytical methods, confirming process consistency, and building the knowledge needed for scale-up and GMP manufacturing.
They say a strong analytical foundation is essential to turning innovative science into a manufacturing-ready therapy.
An ADC payload–linker program puts impurity profiling, robust methods, and process consistency ahead of GMP scale-up.
Their recurring priority is designed-in control, not after-the-fact confirmation
Across the posts, Pawel Olszowy returns to one principle: decisions made earlier in development are stronger than artifacts produced later.
Read more
ICH Q12 helps design flexibility in before approval; impurity control requires explaining impurity formation and purge, not merely passing a release test; and PAT delivers value when built into validated models and operating ownership, not simply installed.
Each post moves from a misconception or question to a framework and its practical manufacturing consequences.
The focus is on development decisions, not documents, tests, or tools.
Established conditions in a dossier, a demonstrated purge study, or a validated analytical model can each create options later—not just add paperwork or equipment.
Shows why a passing release test does not prove a process is well controlled.
Read more
It sets out Olszowy's core argument: analytical development should explain impurity formation and control, not just confirm a batch.
Pawel Olszowy argues that a passing end-product release test proves batch quality but does not show where or why an impurity formed, whether the process stayed in control, or whether the next batch will behave the same way.
The post recommends impurity control strategies that track origin, fate and purge across the whole process; define critical process parameters around impurity formation; design meaningful in-process controls; demonstrate impurity purge scientifically; and treat end-product testing as confirmation rather than the primary safeguard.
It also points to digital twins and model-based process development to simulate mixing, temperature, reaction time, solvent selection and crystallization before a process is locked, allowing in-process controls and Process Analytical Technology to be placed where they have the greatest impact.
For brands planning a campaign
A campaign about pharmaceutical quality, analytical development or process analytics can use this post to move the conversation beyond release testing. Its practical hook is process understanding: impurity origin and purge, model-based development, and better placement of PAT and in-process controls.
Shows why post-approval change planning starts during development, not after approval.
Read more
It introduces the basics of ICH Q12 and lifecycle management.
Pawel Olszowy argues that ICH Q12's biggest advantage is not faster variations but the ability to design flexibility into a product before the first commercial batch.
The post explains three tools: Established Conditions identify which dossier elements are critical to product quality and which can be managed with more flexibility through the Pharmaceutical Quality System; Post-Approval Change Management Protocols let a company agree with regulators in advance on the data, studies and acceptance criteria for future manufacturing changes; and the Product Lifecycle Management document brings those commitments into a living roadmap for the commercial lifecycle.
They list business drivers such as a second manufacturing site, a new supplier, higher production volumes, a more efficient process and greater supply chain resilience, and say companies handle these changes best when they plan long before they need to.
The post also states that at Polpharma, lifecycle management is seen as part of development.
For brands planning a campaign
A regulatory, CMC or lifecycle-management campaign can use this post to show that change readiness is a development decision. It offers a concrete framework for discussing Established Conditions, PACMPs and PLCM with brand, agency or CDMO audiences.
Shows what analytical development contributes to an ADC manufacturing program, with a concrete example of how analytical work supports scale-up and GMP manufacturing of complex drug components.
Read more
Pawel Olszowy shares a collaboration in which Polpharma API will support GMP scale-up and manufacturing of an MMAE-based payload–linker for an ADC program with Celon Pharma S.A.
The post says analytical development gives process development and manufacturing teams the understanding to make informed decisions.
For complex payloads, linkers and payload–linkers, that means understanding impurity profiles, developing robust analytical methods, confirming process consistency and generating knowledge for scale-up and GMP manufacturing.
They say a strong analytical foundation is essential to turning innovative science into a manufacturing-ready therapy, and that the analytical teams are contributing to Celon Pharma's ADC program.
For brands planning a campaign
An ADC, CDMO or complex-API campaign can lead with analytical readiness rather than general capability claims. This named collaboration connects impurity profiling, robust methods and process consistency to GMP scale-up.
Shows what it takes to implement PAT and why the work often takes years.
Read more
It gives newcomers a realistic view of the people, systems and validation behind real-time manufacturing insight.
Pawel Olszowy argues that PAT is more than a set of analytical tools: it reflects how far small-molecule manufacturing has evolved, with in-line and at-line tools monitoring critical quality attributes during synthesis, granulation and tableting.
Effective implementation requires validated analytical models, robust integration with platforms such as LIMS and MES, and cross-functional ownership across R&D, manufacturing and QA; the process often takes years rather than months.
Benefits include faster, more confident batch-release decisions, earlier detection of process deviations, less rework and material loss, and greater consistency in technology transfer between sites.
They also say that at Polpharma API, PAT is part of a broader transformation in API manufacturing, with process data, automation and advanced monitoring increasingly embedded in development and production.
For brands planning a campaign
A process analytics, automation or manufacturing technology campaign can address the implementation barriers buyers face: validated models, LIMS and MES integration, and cross-functional ownership. The post supports a message about real-time decision-making and technology transfer, not just tool features.
A recurring method: technical principle to manufacturing decision4
Plan for post-approval change before the first commercial batch1
Impurity control needs process understanding, not just release testing1
PAT is a multiyear operating change, not a tool purchase1
Analytical development as the base for ADC scale-up and GMP manufacturing1
Plan for post-approval change before the first commercial batch
Pawel Olszowy argues that waiting until after approval to think about post-approval changes is already too late.
Read more
They describe ICH Q12 less as a route to faster variations and more as a way to build flexibility into a product before the first commercial batch is released.
The named tools are Established Conditions, Post-Approval Change Management Protocols, and a Product Lifecycle Management document.
The business triggers they list include a second manufacturing site, a new supplier, higher production volumes, a more efficient process, and greater supply-chain resilience.
Their conclusion: companies that handle these changes well planned for them long before they were needed.
For brands planning a campaign
A brand discussing lifecycle management, CMC change strategy, or supply-chain resilience can use this framing to argue for early regulatory design and practical ICH Q12 adoption.
Impurity control needs process understanding, not just release testing
Pawel Olszowy calls the belief that a passing release test proves a well-controlled process the most dangerous illusion in pharmaceutical manufacturing.
Read more
A release test confirms batch quality, but not where or why an impurity formed, whether the process stayed in control, or whether the next batch will behave the same way.
Their approach defines critical process parameters around impurity formation, designs meaningful in-process controls, demonstrates impurity purge scientifically, and treats end-product testing as confirmation rather than the primary safeguard.
They also point to digital twins and model-based process development to simulate how mixing, temperature, reaction time, solvent choice, and crystallization affect impurity formation and purge before a process is locked.
For brands planning a campaign
For a brand focused on impurity control, analytical development, or model-based process design, this offers a direct argument for investing in process understanding and placing PAT where it has the greatest effect on control.
PAT is a multiyear operating change, not a tool purchase
Pawel Olszowy presents process analytical technology as more than a set of analytical instruments: they describe it as evidence of how far small-molecule manufacturing has evolved from retrospective quality control to real-time insight.
Read more
In-line and at-line tools monitor critical quality attributes during synthesis, granulation, and tableting.
They name validated analytical models, robust integration with platforms such as LIMS and MES, and cross-functional ownership across R&D, manufacturing, and QA as implementation requirements.
They say implementation often takes years rather than months.
The payoffs they list include faster and more confident batch release, earlier detection of deviations, less rework and material loss, and more consistent technology transfer between sites.
Frames the topic as a question, then separates the tool layer from the operating-model layer.
For brands planning a campaign
A campaign about PAT, digital manufacturing, or CDMO transformation can use this to set realistic buyer expectations: the value depends on models, systems integration, and cross-functional ownership.
Analytical development as the base for ADC scale-up and GMP manufacturing
In a collaboration announcement with Celon Pharma S.A., Pawel Olszowy says Polpharma API will support GMP scale-up and manufacturing of an MMAE-based payload-linker for an ADC program.
Read more
The post uses the project to make a broader point: analytical development builds the understanding that lets process development and manufacturing teams make informed decisions. For complex payloads, linkers, and payload-linkers, they identify impurity profiles, robust analytical methods, process consistency, and knowledge for scale-up and GMP manufacturing as the analytical work that turns innovative science into a manufacturing-ready therapy.
This corporate collaboration announcement shows the argument in a live commercial project. Ask for independent project performance data.
For brands planning a campaign
A brand selling analytical development, CMC services, or ADC manufacturing support can assess this as a concise example of how analytical work is positioned at the front end of scale-up.
A recurring method: technical principle to manufacturing decision
Across the four posts, Pawel Olszowy tends to open with a misconception or question, explain the technical principle, and translate it into operating choices.
Read more
Recurring subjects include impurity formation and purge, model-based process development, PAT implementation, ICH Q12 lifecycle planning, and analytical support for complex ADC components. The format is short, argument-led LinkedIn posts with bulleted practical consequences rather than long-form tutorials or data-heavy technical papers.
Each post moves from a challenge or misconception to a framework, then to practical consequences or a question for readers.
For brands planning a campaign
A brand can assess Pawel Olszowy as a source for concise, decision-oriented pharma manufacturing content.
The posts emphasize strategic framing and implementation logic over deep regulatory text or detailed experimental data.
Ask for those details if they are central to the campaign.
Pawel Olszowy’s posts place them at Polpharma API, Polpharma’s API manufacturing arm, and describe analytical development, process understanding and manufacturing work there.
Read more
The posts also describe a collaboration between Polpharma API and Celon Pharma for GMP scale-up and manufacturing of an ADC payload-linker. Ask for details if sponsorship or affiliate arrangements matter to your decision.
Polpharma API
Employment
Olszowy writes in the first person about work at Polpharma API, describing “our development and production environments” and “our analytical teams” contributing to customer programs.
Olszowy announced a new collaboration between Polpharma API and Celon Pharma S.A. to support GMP scale-up and manufacturing of an MMAE-based payload-linker for an ADC program.
Read more
The post does not state the contract terms or duration.
Pawel Olszowy writes short, argument-led posts about pharmaceutical manufacturing.
Read more
A consistent theme is that decisions affecting product quality and supply resilience are made during development, not at the release test or after approval.
Start with the post on release testing and impurity control, which lays out the reasoning behind many of the other pieces.
Then read the ICH Q12 piece on designing post-approval change into a product before the first commercial batch, followed by the post on process analytical technology as a multiyear operating change rather than a tool purchase.
The ADC payload–linker collaboration announcement applies the same argument to a live program, positioning analytical development ahead of GMP scale-up.
The posts follow a recognisable pattern: a misconception or quoted question, the underlying technical principle, and the operating choices that follow.
Readers can explore the topic tags below and creators listed alongside Olszowy who cover adjacent manufacturing and analytics subjects.
Both write short, first-person posts about the unglamorous work of moving a formulation from the laboratory into production: upscaling, intermediate scale-up trials, reference samples, and handoffs among R&D, production, quality control, regulatory, and purchasing.
Read more
Gulzar writes about personal care and skincare manufacturing, drawing lessons about team communication, trust, and leadership during a heavy production push. Olszowy writes about pharmaceutical API manufacturing, focusing on technical control: impurity purge, established conditions, and validated analytical models.
Both treat digital models as a way to make manufacturing decisions before committing physical resources.
Read more
Adavani's posts on factory digital twins and simulation align with Olszowy's case for model-based process development and simulation of impurity formation and purge.
Adavani covers factory-scale digital twins across industries, laying out maturity levels, data sources, and use cases in an analyst-and-vendor register, with links to market research. Olszowy stays within pharmaceutical process control, tying modelling to specific development choices.
Both write about manufacturing technology through the question of how systems connect.
Read more
Katzman describes cloud-native CAD and PLM linking engineering data across the product lifecycle; Olszowy describes process analytical technology that works only when integrated with platforms such as LIMS and MES.
Katzman writes as a software executive, announcing releases and year-in-review milestones in a product and company news rhythm. Olszowy focuses on development and analytical decisions rather than product announcements, using commercial news only to illustrate a technical argument.
Placement decision: the measurable audience signal is small and specialist.
Read more
Pawel Olszowy has 1,439 LinkedIn followers as of 2026-10-08, making this targeted distribution rather than mass reach.
The four posts address pharmaceutical manufacturing and analytical-development professionals: ICH Q12 lifecycle planning, impurity control, PAT implementation, and an ADC payload-linker collaboration.
The audience is most relevant for campaigns focused on process development, CMC or regulatory flexibility, or CDMO technical credibility.
Ask for recent results or audience-survey data on comparable process-development and regulatory-compliance topics, including job function, seniority, and geography if available.
Pawel Olszowy’s posts focus on pharmaceutical manufacturing and analytical development, covering impurity control and digital twins, ICH Q12 lifecycle planning, process analytical technology implementation, and Polpharma API’s analytical work.
Read more
One post announces a collaboration between Polpharma API and Celon Pharma on GMP scale-up and manufacturing of an MMAE-based payload-linker for an ADC program.
It describes a company-to-company manufacturing agreement, not a creator sponsorship offer.
No sponsorship formats, brand-collaboration terms, rates, or partnership inquiry route are published.
Before planning, a brand should ask directly about available formats, usage rights, review cycles, disclosure practices, rates, and how to inquire about partnerships.
A pharmaceutical manufacturer or CDMO wants to explain why process understanding matters more than relying on a passing release test.
Decision
Good subject fit for an educational post, subject to confirming commercial terms directly. Pawel Olszowy explains what release testing cannot establish, then connects impurity origin and purge to process parameters, in-process controls, and model-based development. The result is a clear argument for a technical audience, not a generic quality claim. The audience signal is specialist but modest: 1,439 LinkedIn followers were reported on 8 October 2026. Ask for audience-role and engagement data before relying on the profile for buyer access.
Sources
Brief
A CMC or regulatory-services brand wants to help development teams plan manufacturing changes before commercial launch.
Decision
Good subject fit for a practical ICH Q12 explainer. Pawel Olszowy names Established Conditions, Post-Approval Change Management Protocols, and the Product Lifecycle Management document, and ties them to business changes such as a new supplier, site transfer, or higher production volumes. The central point—that flexibility should be planned before the first commercial batch—fits a campaign focused on lifecycle strategy. The brand should validate technical claims and avoid implying that regulatory outcomes are guaranteed.
Sources
When to choose a specialist
Read more
Brief
A consumer-health brand wants a broad-reach lifestyle endorsement or a campaign promising mass awareness.
Decision
Poor fit based on the available posts. The LinkedIn following is 1,439, and the content focuses on specialist pharmaceutical manufacturing, not consumer health. Ask for audience demographics, engagement results, and sponsored-performance data before assessing reach or buyer access.
Sources
Brief
A software vendor wants a product demo or a claim that purchasing its PAT platform will quickly deliver manufacturing gains.
Decision
Weak fit for that claim or format. Pawel Olszowy’s PAT post emphasizes validated models, integration with LIMS and MES, and cross-functional ownership, and says implementation often takes years rather than months. It supports an implementation-focused discussion, not a simple tool endorsement or guaranteed return-on-investment claim. Confirm availability and campaign terms directly; no sponsorship formats or terms are documented.
Sources
A worked campaign example
Brief
A CDMO services company wants to reach pharmaceutical development leaders considering analytical development and GMP scale-up for complex ADC components.
Campaign angle
From analytical understanding to GMP scale-up: explain how impurity profiles, robust analytical methods, and process-consistency evidence help teams make informed scale-up decisions for complex payload–linkers.
Execution
Invite Pawel Olszowy to develop a short, technically reviewed LinkedIn post tracing the stages from analytical characterization to scale-up readiness. Use the Celon Pharma collaboration only as the stated example, with permission and appropriate company review, and distinguish the described work from measured outcomes. Ask the client’s technical team to verify every process and capability claim before publication. Before commissioning, confirm availability for paid work and agree on format, fee, disclosure, review process, and usage rights in writing.
Fit decision
Good thematic fit for a technical LinkedIn post, but commercial availability and terms are unverified. The collaboration post offers a concrete example involving Polpharma API, Celon Pharma, and GMP scale-up and manufacturing of an MMAE-based payload–linker. It links analytical work—impurity profiling, robust methods, and process consistency—to manufacturing readiness. The post describes the collaboration from Pawel Olszowy’s perspective; ask for independent performance results before making outcome claims.
Naeem Gulzar when the campaign is about getting a formulated product into reproducible production, not pharmaceutical process development or regulatory strategy.
Two posts describe coordinating product development, sales and marketing, production, quality control, regulatory, and purchasing to take skincare and suncare formulations from laboratory work to full production at KLG Liquida, part of the KLAPP Skin Care Science group.
They cover a customer approving a formulation after a single sampling round, supplier discussions when standard ordering was not enough, and intermediate scale-up trials with reference samples and laboratory support during production.
Gulzar is the better choice for campaigns seeking a first-person account of cross-functional teamwork, short-cycle launches, and shop-floor problem solving in personal care—told in a register marketing teams can reuse without heavy editing.
The posts answer whether this person can speak credibly about the process through coordination detail, rather than analytical or regulatory depth.
Pawel Olszowy’s posts do not cover pharmaceutical substance development: they say nothing about impurity control, process analytical technology, ICH Q12, CMC strategy, regulatory filing content, or GMP scale-up of a drug substance.
A campaign promising pharmaceutical development or regulatory insight would need expertise from elsewhere, and the teamwork framing would need to be rewritten for a pharmaceutical manufacturing audience.
Ask whether paid work is available and what the commercial terms are.
Choose Santi Adavani when the campaign is about digital twins, simulation, and Industry 4.0 adoption across manufacturing, rather than a specific drug process or regulatory pathway.
Read more
The posts cover production scheduling, bottleneck identification that spreadsheets miss, layout testing before construction, predictive maintenance, workforce planning, and a staged maturity model from descriptive twins upward, including automotive asset modelling, engineering design simulation, and VR showrooms.
They name the data sources a factory twin draws on, such as PLC, MES, and IoT feeds, inventory levels, demand forecasts, and maintenance logs, and give adoption figures.
That structure suits an educational post for operations or digital-transformation leaders deciding where to start, and travels across manufacturing sectors.
Adavani is the better choice when campaign reach extends beyond pharmaceuticals or the message is about technology adoption rather than process understanding.
The content is a category overview, not a firsthand account.
It asserts benefits and cites adoption numbers via a third-party article link, so verify any practical claim against the underlying source before publication.
The posts do not cover pharmaceutical CMC, impurity, or regulatory filing detail.
For a pharmaceutical process-development campaign, ask what domain expertise another contributor can provide.
Choose David Katzman when the campaign targets product development software and engineering decision-makers, rather than pharmaceutical process and regulatory work.
Read more
The posts are release- and milestone-driven: a cloud-native design and simulation workflow built with NVIDIA for robotics teams, a cloud-native model-based definition capability, an AI advisor embedded in the design environment, PLM for regulated industries on government cloud, integrations between PCB design and mechanical CAD, and an annual roundup of customer adoption, a new Melbourne office, and a Gartner positioning.
A second post introduces a platform release for connecting systems, automating workflows, and keeping product data moving across the lifecycle.
This suits campaigns aimed at buyers seeking a vendor-side view of product development tooling and a message tied to software capabilities and roadmap, with an audience of engineering and IT leadership in discrete manufacturing.
The angle is commercial product, not neutral analysis.
Much of the content is company milestone and release communication, so a campaign built on it inherits the vendor’s framing and stays within what the vendor already publishes.
The posts do not cover pharmaceutical process development, impurity control, process analytical technology, or regulatory strategy.
For an independent technical argument aimed at a pharmaceutical audience, ask what expertise is available to support it.
Four full LinkedIn posts by Pawel Olszowy cover impurity control and model-based process development, ICH Q12 lifecycle planning, process analytical technology implementation, and an announced Polpharma API collaboration with Celon Pharma on GMP scale-up of an ADC payload–linker.
Six posts from three other manufacturing and analytics creators provide comparison.
The posts carry no publication dates, so the order and recency of the themes are not established.
No video transcripts, standalone articles, or independent company documents are included here, and audience information is limited to a reported LinkedIn follower count of 1,439 observed on 8 October 2026; no role, engagement, or sponsorship details are published.